首页> 外文OA文献 >PCN72 COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1–98 AND ATAC TRIALS:A UK PERSPECTIVE

【2h】

PCN72 COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1–98 AND ATAC TRIALS:A UK PERSPECTIVE

机译：使用大1–98和ATAC试验的更新生存数据，来昔洛特对早期乳腺癌的绝经后妇女进行辅助治疗时，左唑和纳曲唑对他莫昔芬的PCN72成本效益：英国的观点

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Karnon J; Kaura S;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial [J] . Gershon Y. Locker, Robert Mansel, David Cella, Breast Cancer Research and Treatment . 2007,第2期

机译：阿那曲唑与他莫昔芬作为绝经后早期乳腺癌女性患者的主要辅助治疗的成本-效果分析：美国医疗保健系统的观点。对ATAC（“ Arimidex”，他莫昔芬单独治疗或联合治疗）的5年完成治疗分析
2. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen [J] . Locker GY, Mansel R, Cella D, Breast cancer research and treatment. . 2007,第2期

机译：阿那曲唑与他莫昔芬作为绝经后早期乳腺癌女性患者的主要辅助治疗的成本-效果分析：美国医疗保健系统的观点。对ATAC（'Arimidex'，他莫昔芬，5年完成的治疗分析
3. 28 Applying survival based cost-effectiveness analyses to estimate the impact of patent expiry on the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer [J] . J.Karnon, S.Kaura European Journal of Cancer Supplements . 2010,第3期

机译：28应用基于生存的成本-效果分析来评估专利到期对来曲唑和阿那曲唑与他莫昔芬作为他莫昔芬辅助治疗绝经后早期乳腺癌妇女的成本-效果的影响
4. Aromatase Inhibitors in Prevention - Data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial and the Design of IBIS-II (the Second International Breast Cancer Intervention Study) [C] . Jack Cuzick International Society of Cancer Chemoprevention . 2003

机译：预防芳族酶抑制剂 - 来自ATAC（ARIMIDEX，Tamoxifen单独或组合或组合的数据）的数据和IBIS-II的设计（第二次国际乳腺癌干预研究）
5. Dietary associations with biomarkers of breast cancer risk in women on adjuvant tamoxifen therapy. [D] . Strom, Meghan Brianna. 2016

机译：辅助性他莫昔芬治疗妇女饮食中与乳腺癌风险生物标志物的关联。
6. Pharmacokinetics of anastrozole and tamoxifen alone and in combination during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial [O] . The ATAC Trialists Group 2001

机译：绝经后妇女在早期乳腺癌的辅助内分泌治疗中单独使用或联合使用阿那曲唑和他莫昔芬的药代动力学： Arimidex™和他莫昔芬单独或联合使用（ATAC）试验的子协议
7. PCN116 A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE [O] . El Ouagari K, Kaura S, Karnon JD 2009

机译：PCN116基于生存期的5年来特罗唑对他莫昔芬作为早期乳腺癌绝经后妇女辅助治疗的费用效果分析：加拿大的观点

PCN72 COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1–98 AND ATAC TRIALS:A UK PERSPECTIVE

著录项

相似文献

相关主题

期刊订阅